Trial reportOncotarget2015
Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
Trial report in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer.International journal of molecular sciences · 2023Pooled it
- Exosomal microRNAs as tumor markers in epithelial ovarian cancer.Molecular oncology · 2018Trial
- MicroRNA Expression in Breast Cancer Patients, an Integrative Review.Journal of surgical oncology · 2026Review
- MicroRNA-mediated regulatory mechanisms in cow's ileum and ileum lymph node in response to Mycobacterium avium subspecies paratuberculosis infection.Scientific reports · 2025Article
- Molecular Biology of Cancer-Interplay of Malignant Cells with Emerging Therapies.International journal of molecular sciences · 2024Article
- Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement.Biochemia medica · 2024Review
- An overview of challenges associated with exosomal miRNA isolation toward liquid biopsy-based ovarian cancer detection.Heliyon · 2024Review
- Identification of Gene Expression in Different Stages of Breast Cancer with Machine Learning.Cancers · 2024Article
- Machine Learning Gene Signature to Metastatic ccRCC Based on ceRNA Network.International journal of molecular sciences · 2024Article
- MiR-146a Restoration Suppresses Triple-Negative Breast Cancer Cell Migration: A Bioinformatic andAdvanced pharmaceutical bulletin · 2022Article
- The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer.Molecular cancer · 2022Review
- A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer.International journal of molecular sciences · 2021Article
- Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites.Scientific reports · 2021Article
- Article
- PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.Journal of clinical laboratory analysis · 2021Article
- Clinico-Pathological Importance of miR-146a in Lung Cancer.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- A comprehensive review on oncogenic miRNAs in breast cancer.Journal of genetics · 2021Review
- Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study.International journal of molecular sciences · 2020Article
- Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets.International journal of molecular sciences · 2020Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the multicenter SUCCESS trial, we investigated the association of plasma microRNAs with different subtypes of invasive breast cancer.Six miRs (miR-16, miR-27a, miR-107, miR-130a, miR-132 and miR-146a) were selected from microarray profiling and further validated in plasma of 111 breast cancer patients before and after chemotherapy and 46 healthy women by quantitative real-time PCR.Plasma levels of miR-16 (p = 0.0001), miR-27a (p = 0.039) and miR-132 (p = 0.020) were higher in breast cancer patients before chemotherapy than healthy women. With the exception of miR-16, the increased levels of miR-27a (p = 0.035) and miR-132 (p = 0.025) decreased after chemotherapy to those observed in healthy women. Levels of miR-16 (p = 0.019), miR-107 (p = 0.036), miR-130a (p = 0.027) and miR-146a (p = 0.047) were different between lymph node -positive and -negative patients, while the levels of miR-130a (p = 0.001) and miR-146a (p = 0.025) also differed between HER2-positive and -negative status. Estrogen-receptor negative tumors displayed higher concentrations of circulating miR-107 than their counterparts (p = 0.035). However, overexpression of miR-107 in MCF-7 cells did not downregulate estrogen receptor protein. Altered expression levels of miR-107 influenced the migration and invasion behavior of MCF-7 and MDA-MB-231 cells.Our data indicate differential concentrations of plasma miR-16, miR-107, miR-130a and miR-146a in different breast cancer subtypes, suggesting a potential role of these miRs in breast cancer biology and tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.